Home › Funds › CIDEL ASSET MANAGEMENT INC › ABT

CIDEL ASSET MANAGEMENT INC position in ABT

ABBOTT LABORATORIES · Health Care

CIDEL ASSET MANAGEMENT INC reported holding 227,618 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$22.5M, representing 1.09% of its reported portfolio and ranking #27 among its reported holdings. CIDEL ASSET MANAGEMENT INC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)227.62K sh
Reported value held$22.50M
Portfolio Weight1.09%
First reportedQ4 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How CIDEL ASSET MANAGEMENT INC's ABT position evolved

CIDEL ASSET MANAGEMENT INC first disclosed a stake in ABT in Q4 2023 at 5,779 shares (US$636K). The position peaked in Q3 2025 at 335,841 shares, worth US$45.0M. Across 12 filings, CIDEL ASSET MANAGEMENT INC increased the stake 8 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 227,618 shares valued at US$22.5M. Notable position changes include a 2870% increase in Q3 2024 (shares were roughly flat over the following quarter), a 63% increase in Q4 2024 (shares rose 18% over the following quarter), a 45% trim in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 5.78K $636.10K New
Q1 2024 6.06K $688.33K Add
Q2 2024 6.64K $689.96K Add
Q3 2024 197.20K $22.48M Add
Q4 2024 321.22K $36.33M Add
Q1 2025 325.52K $43.18M Add
Q2 2025 329.18K $44.77M Add
Q3 2025 335.84K $44.98M Add
Q4 2025 322.23K $40.37M Reduce
Q1 2026 412.39K $42.34M Add
Q2 2026 227.60K $20.65M Reduce
Q3 2026 227.62K $22.50M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has CIDEL ASSET MANAGEMENT INC held ABT?

CIDEL ASSET MANAGEMENT INC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is CIDEL ASSET MANAGEMENT INC's current position in ABT?

As of Q3 2026, CIDEL ASSET MANAGEMENT INC holds 227.62K shares of ABT (ABBOTT LABORATORIES), valued at $22.50M, representing 1.09% of its reported portfolio and ranking #27.

Has CIDEL ASSET MANAGEMENT INC been buying or selling ABT?

In the latest 13F filing (Q3 2026), CIDEL ASSET MANAGEMENT INC held unchanged its position in ABT. The position peaked in Q3 2025 at 335.84K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.